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PRESCRIBING FOLLOWING ROBOTIC RADICAL PROSTATECTOMY
Brett Watson, MD1, Ross Touriel2, Joshua Volin2, Frank Burks, MD1
1
Beaumont Health, Dept of Urology, Royal Oak, MI, 2Oakland University William Beaumont
School of Medicine, Rochester, MI
Presented By: Mit Shah, MD, BS
Introduction: Various strategies have been explored to decrease the quantity of opioids
prescribed for post-operative pain. The Michigan Opioid Prescribing Engagement Network,
in partnership with BCBS-Michigan, has developed a pain optimization pathway for several
surgical procedures, including prostatectomy. Urologists who follow the pain optimization
pathway, which includes pre-operative patient education and limiting discharge opioids to 6
tablets of oxycodone 5 mg, can report a modifier for additional reimbursement. We explored
the impact of this incentive on inpatient opioid prescribing practices following robotic
assisted radical prostatectomy (RARP).
Methods: Patients undergoing RARP between January 2017 and August 2019 at a single
institution were retrospectively reviewed. This interval included cases both before, and after,
the reimbursement incentive was implemented on July 1, 2018. Outcomes included quantity
of opioid administered during hospitalization, reported in morphine milligram equivalents
(MME), and average inpatient pain scores, reported with numerical pain scale.
Results: A total of 300 patients underwent RARP, 209 prior to implementation of the
reimbursement incentive, and 91 after. Mean MME administered during hospitalization
decreased 18% after the incentive went into effect, from 73 to 54 MME (p=0.04). There was
no difference in average pain scores or length of stay.
Conclusion: For patients undergoing RARP, a reimbursement-based incentive tied
to limiting outpatient opioid prescriptions was associated with a decrease in opioids
administered during hospitalization, with no impact on subjective pain scores or length of
stay. This may reflect the effectiveness of pre-operative patient education on the dangers of
opioid use and alternative pain management options.
Funding: N/A
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Introduction: Our objective was to evaluate the cost-effectiveness of obtaining preoperative
type and screen (TS) for common urological procedures and to determine patient and
hospital factors associated with receiving blood transfusions.
Methods: Retrospective database analysis of the 2006-2015 Nationwide Inpatient Sample
(NIS) was performed to identify patients undergoing a variety of urological procedures. A
total of 4,113,144 cases were identified. Transfusion rates were then determined from NIS
data, and multivariate regression analyses was used to identify factors associated with
transfusions. A cost-effectiveness analysis was performed to determine the incremental
cost-effectiveness ratio (ICER) of obtaining preoperative TS to prevent an emergencyrelease transfusion (ERT), with a willingness-to-pay threshold of $1,500.
Results: Transfusion rates of common urological procedure ranged from .91% to 33.14%.
On multivariate modeling, all comorbidities with the exception of obesity were significantly
associated with blood transfusion. Some examples included diabetes (OR, 1.26; 95% CI,
1.19-1.33), liver disease (OR, 1.20; 95% CI, 1.13-1.29), and metastatic cancer (OR, 2.69;
95% CI 2.54-2.85) (p < 0.01 for all). One-way sensitivity analysis demonstrated that the risk
of transfusion should exceed 4.12% to justify preoperative TS. The ICER of preoperative TS
for radical prostatectomy (transfusion rate = 3.88%) and penile implants (transfusion rate =
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0.91%) were $1,607 and $7,709 per ERT prevented, respectively.
Conclusion: Based on a large national database, institutions should consider a risk of
transfusion greater than or equal to 4.12% to justify a preoperative TS. A selective TS policy
for high-risk patients may reduce costs and unnecessary workload for laboratory staff.
Funding: N/A
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Introduction: The receipt of industry payments has been associated with pharmaceutical
prescribing, surgical device selection, and research findings. Recent studies suggest that
payments may be associated with positive positions in editorials and reviews. The Urolift
device, manufactured by NeoTract LLC, has mixed results compared to TURP for lower
urinary tract symptoms. Our goal was to examine associations between authors’ financial
conflicts-of-interest and their published comments on the Urolift device.
Methods: We searched Google Scholar for all articles that cite the 2013 L.I.F.T. study in
Journal of Urology. We screened for editorials or reviews written by American authors. Two
blinded attending urologists coded included articles as favorable or neutral. A separate
blinded researcher recorded conflict-of-interest data using the Open Payments Registry.
Results: We identified 13 articles by 15 unique authors. Since 2014, these authors have
collectively received $270,000 from NeoTract. 3 papers were coded as favorable, and 10
papers were coded as unfavorable. All (4/4; 100%) authors of favorable articles received
payments, while 5/12 (41.7%) authors of neutral papers had payments. From the 8 unique
authors with payments from Neotract, there were only two disclosures.
Conclusion: These data suggest a relationship between payments from a manufacturer
and positive published position on that company’s device. Further work is needed in this
area.

Funding: N/A

Table of Contents

Pg 98

